​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals stock forecast is as follows: an average price target of $521.64 (represents a 18.15% upside from VRTX’s last price of $441.52) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.

VRTX Price Target

The average price target for Vertex Pharmaceuticals (VRTX) is $521.64 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $600.00 to $361.00. This represents a potential 18.15% upside from VRTX's last price of $441.52.

VRTX Analyst Ratings

Buy

According to 20 Wall Street analysts, Vertex Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VRTX stock is 0 'Strong Buy' (0.00%), 11 'Buy' (55.00%), 8 'Hold' (40.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).

Vertex Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 10, 2025Terence FlynnMorgan Stanley$456.00$409.5611.34%3.28%
Dec 19, 2024Brian AbrahamsRBC Capital$400.00$469.22-14.75%-9.40%
Dec 09, 2024Michael YeeJefferies$550.00$462.1019.02%24.57%
Nov 05, 2024Hartaj SinghOppenheimer$540.00$499.108.19%22.30%
Nov 05, 2024Brian AbrahamsRBC Capital$451.00$499.88-9.78%2.15%
Oct 22, 2024Whitney IjemCanaccord Genuity$361.00$478.09-24.49%-18.24%
Oct 21, 2024Evan David SeigermanBMO Capital$566.00$485.7416.52%28.19%
Oct 21, 2024Salveen RichterGoldman Sachs$598.00$483.0023.81%35.44%
Oct 14, 2024Geoff MeachamBank of America Securities$541.00$482.1212.21%22.53%
Oct 09, 2024Brian AbrahamsRBC Capital$437.00$458.94-4.78%-1.02%
Aug 05, 2024Joon LeeTruist Financial$550.00$494.4611.23%24.57%
Aug 05, 2024Hartaj SinghOppenheimer$550.00$477.8615.10%24.57%
Aug 05, 2024Andy ChenWolfe Research$576.00$476.9120.78%30.46%
Aug 02, 2024Andrew FeinH.C. Wainwright$600.00$505.7818.63%35.89%
Jun 17, 2024Jasper HellwegArgus Research$550.00$474.6115.88%24.57%
Jun 11, 2024Brian AbrahamsRBC Capital$421.00$483.28-12.89%-4.65%
May 31, 2024Evan David SeigermanBMO Capital$500.00$443.0512.85%13.25%
May 07, 2024Christopher RaymondRaymond James$456.00$413.4210.30%3.28%
May 07, 2024Brian AbrahamsRBC Capital$424.00$402.505.34%-3.97%
Apr 11, 2024Andrew FeinH.C. Wainwright$462.00$397.5816.20%4.64%
Apr 11, 2024Liisa BaykoEvercore ISI$438.00$397.5810.17%-0.80%
Feb 08, 2023Morgan Stanley$285.00$297.18-4.10%-35.45%
Feb 08, 2023H.C. Wainwright$326.00$308.545.66%-26.16%
Feb 08, 2023Leerink Partners$365.00$308.5418.30%-17.33%
Nov 17, 2022Argus Research$340.00$310.869.37%-22.99%
Aug 08, 2022Morgan Stanley$253.00$290.68-12.96%-42.70%
Aug 05, 2022H.C. Wainwright$300.00$279.547.32%-32.05%
Jul 12, 2022Olivia BrayerCantor Fitzgerald$365.00$290.0125.86%-17.33%
Jul 11, 2022Paul MatteisStifel Nicolaus$240.00$295.46-18.77%-45.64%
Jul 02, 2022Jasper HellwegArgus Research$280.00$287.32-2.55%-36.58%
Jun 13, 2022Cowen & Co.$310.00$248.9624.52%-29.79%
May 03, 2022Matthew HarrisonMorgan Stanley$250.00$261.96-4.57%-43.38%
Apr 22, 2022Piper Sandler$249.00$279.02-10.76%-43.60%
Apr 06, 2022Hartaj SinghOppenheimer$350.00$272.3928.49%-20.73%
Mar 22, 2022Evan SeigermanBMO Capital$274.00$251.888.78%-37.94%
Mar 22, 2022Brian SkorneyRobert W. Baird$240.00$251.88-4.72%-45.64%
Jan 27, 2022Michael YeeJefferies$275.00$228.2220.50%-37.72%
Jan 27, 2022Andrew GallerWolfe Research$282.00$228.2223.56%-36.13%
Jan 27, 2022Matthew HarrisonMorgan Stanley$208.00$228.22-8.86%-52.89%
Jan 27, 2022Cory KasimovJ.P. Morgan$288.00$228.2226.19%-34.77%
Jan 24, 2022Phil NadeauCowen & Co.$300.00$229.6830.62%-32.05%
Dec 02, 2021Geoff PorgesLeerink Partners$175.00$204.45-14.40%-60.36%
Dec 01, 2021Debjit ChattopadhyayGuggenheim$286.00$205.0039.51%-35.22%
Nov 02, 2021Geoff MeachamBank of America Securities$275.00$181.4051.60%-37.72%
Jun 11, 2021Alethia YoungCantor Fitzgerald$281.00$193.0245.58%-36.36%
Jun 11, 2021Gena WangBarclays$285.00$193.0247.65%-35.45%
May 12, 2021Colin BristowUBS$279.00$212.6831.18%-36.81%

The latest Vertex Pharmaceuticals stock forecast, released on Jan 10, 2025 by Terence Flynn from Morgan Stanley, set a price target of $456.00, which represents a 11.34% increase from the stock price at the time of the forecast ($409.56), and a 3.28% increase from VRTX last price ($441.52).

Vertex Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts1521
Avg Price Target$456.00$479.40$496.52
Last Closing Price$441.52$441.52$441.52
Upside/Downside3.28%8.58%12.46%

In the current month, the average price target of Vertex Pharmaceuticals stock is $456.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 3.28% increase as opposed to Vertex Pharmaceuticals's last price of $441.52. This month's average price target is down -4.88% compared to last quarter, and down -8.16% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2024OppenheimerOutperformPerformDowngrade
Dec 19, 2024RBC CapitalSector PerformSector PerformHold
Nov 13, 2024CitigroupBuyInitialise
Oct 22, 2024Canaccord GenuitySellSellHold
Oct 21, 2024BMO CapitalOutperformOutperformHold
Oct 21, 2024H.C. WainwrightBuyBuyHold
Oct 21, 2024Goldman SachsBuyBuyHold
Oct 17, 2024UBSSector PerformSector PerformHold
Oct 17, 2024UBSBuyBuyHold
Oct 16, 2024ScotiabankSector PerformInitialise
Oct 01, 2024RBC CapitalSector PerformSector PerformHold
Oct 01, 2024Piper SandlerUnderperformUnderperformHold
Oct 01, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Sep 19, 2024Wells FargoSector PerformSector PerformHold
Sep 19, 2024RBC CapitalUnderperformUnderperformHold
Aug 05, 2024OppenheimerOutperformOutperformHold
Aug 05, 2024Wolfe ResearchOutperformOutperformHold
Aug 05, 2024BarclaysOverweightEqual-WeightDowngrade
Aug 02, 2024Piper SandlerOverweightOverweightHold
Jul 31, 2024RBC CapitalUnderperformUnderperformHold
Jul 19, 2024H.C. WainwrightBuyBuyHold
Jul 11, 2024Wells FargoSector PerformSector PerformHold
Jul 11, 2024UBSUnderperformUnderperformHold
Jul 11, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jun 24, 2024Wells FargoOverweightOverweightHold
Jun 11, 2024RBC CapitalSector PerformSector PerformHold
May 31, 2024RBC CapitalUnderperformUnderperformHold
May 31, 2024UBSSector PerformSector PerformHold
May 31, 2024BMO CapitalOutperformOutperformHold
May 07, 2024Piper SandlerOverweightOverweightHold
May 07, 2024RBC CapitalSector PerformSector PerformHold
Apr 12, 2024Wells FargoSector PerformSector PerformHold
Apr 12, 2024RBC CapitalUnderperformUnderperformHold
Apr 11, 2024Evercore ISIOutperformUpgrade
Feb 20, 2024Wells FargoSector PerformSector PerformHold
Jan 31, 2024Stifel NicolausSector PerformSector PerformHold
Jan 31, 2024RBC CapitalUnderperformUnderperformHold
Jan 09, 2024Stifel NicolausSector PerformSector PerformHold
Jan 09, 2024RBC CapitalUnderperformUnderperformHold
Feb 08, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Feb 08, 2023Piper SandlerNeutralNeutralHold
Feb 08, 2023BarclaysOverweightOverweightHold
Feb 08, 2023SVB LeerinkOutperformOutperformHold
Dec 19, 2022Morgan StanleyUnderweightUnderweightHold
Dec 19, 2022JefferiesHoldDowngrade
Nov 17, 2022Argus ResearchBuyBuyHold
Oct 16, 2022Piper SandlerNeutralNeutralHold
Aug 08, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 12, 2022Cantor FitzgeraldOverweightInitialise
Jul 11, 2022Piper SandlerNeutralNeutralHold
Jun 13, 2022Argus ResearchBuyBuyHold
Jun 13, 2022Cowen & Co.OutperformOutperformHold
Jun 01, 2022Maxim GroupBuyUpgrade
May 03, 2022Morgan StanleyUnderweightEqual-WeightUpgrade
May 03, 2022Morgan StanleyUnderweightUpgrade
Apr 05, 2022OppenheimerOutperformOutperformHold

Vertex Pharmaceuticals's last stock rating was published by Oppenheimer on Dec 19, 2024. The company Downgrade its VRTX rating from "Outperform" to "Perform".

Vertex Pharmaceuticals Financial Forecast

Vertex Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$2.48B$2.49B$2.37B$2.30B$2.33B$2.20B$2.10B$2.07B$1.98B$1.79B$1.72B$1.63B$1.54B$1.52B$1.52B$1.41B$949.83M
Avg Forecast$3.39B$3.21B$3.13B$3.03B$3.12B$2.94B$2.84B$2.80B$2.79B$2.69B$2.66B$2.58B$2.51B$2.50B$2.42B$2.34B$2.30B$2.23B$2.13B$2.07B$2.00B$1.86B$1.72B$1.66B$1.59B$1.49B$1.39B$1.30B$1.01B$950.95M
High Forecast$3.58B$3.40B$3.31B$3.20B$3.30B$3.10B$3.01B$2.92B$2.88B$2.69B$2.66B$2.58B$2.56B$2.58B$2.56B$2.47B$2.38B$2.23B$2.13B$2.07B$2.00B$1.86B$1.72B$1.66B$1.59B$1.49B$1.39B$1.30B$1.01B$950.95M
Low Forecast$3.29B$3.12B$3.04B$2.94B$3.03B$2.85B$2.76B$2.76B$2.73B$2.68B$2.66B$2.58B$2.44B$2.42B$2.35B$2.27B$2.25B$2.23B$2.13B$2.07B$2.00B$1.86B$1.72B$1.66B$1.59B$1.49B$1.39B$1.30B$1.01B$950.95M
# Analysts54544348189661225121211111111121212121299955
Surprise %-------------0.99%1.03%1.02%1.00%1.05%1.03%1.01%1.03%1.07%1.04%1.04%1.02%1.04%1.09%1.17%1.39%1.00%

Vertex Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 12 analysts is $2.51B, with a low forecast of $2.44B, and a high forecast of $2.56B. VRTX's average Quarter revenue forecast represents a 1.18% increase compared to the company's last Quarter revenue of $2.48B (Sep 23).

Vertex Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348189661225121211111111121212121299955
EBITDA-------------$1.04B$1.03B$1.25B$1.11B$1.22B$1.05B$962.20M$919.88M$1.13B$2.46M$865.47M$934.27M$786.37M$865.34M$698.49M$717.46M$111.06M
Avg Forecast$1.53B$1.45B$1.41B$1.36B$1.41B$1.32B$1.28B$1.26B$1.25B$1.21B$1.20B$1.21B$1.13B$1.13B$1.09B$1.10B$990.40M$944.75M$903.19M$996.96M$848.40M$786.34M$728.04M$772.17M$674.89M$629.50M$589.97M$430.42M$429.87M$402.87M
High Forecast$1.61B$1.53B$1.49B$1.44B$1.49B$1.40B$1.35B$1.32B$1.30B$1.21B$1.20B$1.45B$1.15B$1.16B$1.15B$1.32B$1.19B$944.75M$903.19M$1.20B$848.40M$786.34M$728.04M$926.60M$674.89M$629.50M$589.97M$516.51M$429.87M$402.87M
Low Forecast$1.48B$1.41B$1.37B$1.32B$1.36B$1.29B$1.24B$1.24B$1.23B$1.21B$1.20B$965.05M$1.10B$1.09B$1.06B$877.32M$792.32M$944.75M$903.19M$797.56M$848.40M$786.34M$728.04M$617.73M$674.89M$629.50M$589.97M$344.34M$429.87M$402.87M
Surprise %-------------0.92%0.94%1.14%1.12%1.29%1.16%0.97%1.08%1.44%0.00%1.12%1.38%1.25%1.47%1.62%1.67%0.28%

12 analysts predict VRTX's average Quarter EBITDA for Dec 23 to be $1.13B, with a high of $1.15B and a low of $1.10B. This is 9.05% upper than Vertex Pharmaceuticals's previous annual EBITDA (Sep 23) of $1.04B.

Vertex Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348189661225121211111111121212121299955
Net Income-------------$1.04B$915.70M$699.80M$818.90M$930.50M$810.50M$762.10M$770.11M$851.93M$66.92M$653.14M$604.19M$667.43M$837.27M$602.75M$583.23M$57.52M
Avg Forecast$1.39B$1.37B$1.36B$1.32B$1.25B$1.21B$1.18B$1.15B$1.05B$1.06B$-3.03B$914.21M$1.06B$1.03B$1.01B$831.10M$829.15M$932.39M$896.54M$755.55M$848.30M$797.46M$653.32M$582.73M$663.24M$605.26M$537.21M$371.43M$313.26M$297.52M
High Forecast$1.50B$1.47B$1.46B$1.42B$1.34B$1.30B$1.26B$1.22B$1.18B$1.07B$-2.92B$1.10B$1.15B$1.13B$1.08B$997.32M$994.98M$932.39M$896.54M$906.66M$848.30M$797.46M$653.32M$699.27M$663.24M$605.26M$537.21M$445.71M$313.26M$297.52M
Low Forecast$1.34B$1.32B$1.31B$1.27B$1.20B$1.17B$1.13B$1.04B$942.46M$1.06B$-3.26B$731.37M$960.03M$861.61M$969.78M$664.88M$663.32M$932.39M$896.54M$604.44M$848.30M$797.46M$653.32M$466.18M$663.24M$605.26M$537.21M$297.14M$313.26M$297.52M
Surprise %-------------1.01%0.91%0.84%0.99%1.00%0.90%1.01%0.91%1.07%0.10%1.12%0.91%1.10%1.56%1.62%1.86%0.19%

Vertex Pharmaceuticals's average Quarter net income forecast for Dec 23 is $1.06B, with a range of $960.03M to $1.15B. VRTX's average Quarter net income forecast represents a 2.53% increase compared to the company's last Quarter net income of $1.04B (Sep 23).

Vertex Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348189661225121211111111121212121299955
SG&A-------------$263.80M$262.60M$241.10M$267.40M$246.80M$215.30M$215.20M$255.16M$198.19M$194.67M$192.08M$211.84M$184.55M$191.80M$182.26M$195.28M$159.67M
Avg Forecast$416.38M$394.83M$384.75M$371.84M$383.11M$360.70M$349.28M$343.70M$342.20M$329.88M$327.20M$258.15M$308.67M$307.28M$297.35M$234.69M$274.73M$274.09M$262.03M$213.35M$246.14M$228.13M$211.22M$171.37M$195.80M$182.63M$171.16M$112.31M$124.72M$116.88M
High Forecast$440.23M$417.45M$406.79M$393.15M$405.06M$381.37M$369.29M$358.92M$353.27M$330.11M$327.20M$309.78M$314.85M$316.72M$314.38M$281.62M$329.67M$274.09M$262.03M$256.02M$246.14M$228.13M$211.22M$205.64M$195.80M$182.63M$171.16M$134.77M$124.72M$116.88M
Low Forecast$404.47M$383.54M$373.75M$361.21M$372.16M$350.39M$339.29M$338.63M$334.81M$329.65M$327.20M$206.52M$300.03M$297.66M$288.85M$187.75M$219.78M$274.09M$262.03M$170.68M$246.14M$228.13M$211.22M$137.10M$195.80M$182.63M$171.16M$89.85M$124.72M$116.88M
Surprise %-------------0.86%0.88%1.03%0.97%0.90%0.82%1.01%1.04%0.87%0.92%1.12%1.08%1.01%1.12%1.62%1.57%1.37%

Vertex Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $308.67M, based on 12 Wall Street analysts, with a range of $300.03M to $314.85M. The forecast indicates a 17.01% rise compared to VRTX last annual SG&A of $263.80M (Sep 23).

Vertex Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts54544348189661225121211111111121212121299955
EPS-------------$4.01$3.55$2.72$3.19$3.63$3.17$2.99$3.02$3.30$0.26$2.52$2.32$2.56$3.22$2.32$2.26$0.22
Avg Forecast$5.33$5.25$5.20$5.05$4.79$4.65$4.51$4.39$4.01$4.08$-11.63$4.07$4.07$3.93$3.86$3.01$3.53$3.61$3.47$3.57$3.29$3.09$2.53$2.70$2.57$2.35$2.08$1.87$1.21$1.15
High Forecast$5.73$5.64$5.59$5.42$5.14$4.99$4.85$4.68$4.51$4.10$-11.19$4.07$4.42$4.34$4.15$3.24$3.69$3.61$3.47$3.57$3.29$3.09$2.53$2.70$2.57$2.35$2.08$1.87$1.21$1.15
Low Forecast$5.13$5.05$5.01$4.86$4.61$4.47$4.34$3.99$3.61$4.06$-12.49$4.07$3.68$3.30$3.72$2.90$3.42$3.61$3.47$3.57$3.29$3.09$2.53$2.70$2.57$2.35$2.08$1.87$1.21$1.15
Surprise %-------------1.02%0.92%0.90%0.90%1.00%0.91%0.84%0.92%1.07%0.10%0.93%0.90%1.09%1.55%1.24%1.86%0.19%

According to 12 Wall Street analysts, Vertex Pharmaceuticals's projected average Quarter EPS for Dec 23 is $4.07, with a low estimate of $3.68 and a high estimate of $4.42. This represents a 1.42% increase compared to VRTX previous annual EPS of $4.01 (Sep 23).

Vertex Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
EDITEditas Medicine$1.34$10.20661.19%Buy
NTLAIntellia Therapeutics$10.12$44.00334.78%Buy
VKTXViking Therapeutics$33.43$98.00193.15%Buy
MRNAModerna$40.72$104.90157.61%Hold
CRBUCaribou Biosciences$1.34$3.00123.88%Buy
BEAMBeam Therapeutics$25.91$50.5094.91%Buy
CRSPCRISPR Therapeutics$41.21$77.5088.06%Buy
VERVVerve Therapeutics$7.70$14.0081.82%Buy
REGNRegeneron Pharmaceuticals$687.27$1.11K61.98%Buy
SRPTSarepta Therapeutics$115.45$184.0059.38%Buy
BMRNBioMarin Pharmaceutical$63.46$92.8546.31%Buy
KRYSKrystal Biotech$156.30$210.3334.57%Buy
VRTXVertex Pharmaceuticals$441.52$521.6418.15%Buy
ALNYAlnylam Pharmaceuticals$273.99$320.5016.98%Buy
PTCTPTC Therapeutics$45.22$50.5011.68%Buy
BNTXBioNTech SE$121.16$127.785.46%Buy
MDGLMadrigal Pharmaceuticals$326.33$315.75-3.24%Buy
DNAGinkgo Bioworks$12.25$7.00-42.86%Buy

VRTX Forecast FAQ

Is Vertex Pharmaceuticals a good buy?

Yes, according to 20 Wall Street analysts, Vertex Pharmaceuticals (VRTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 55.00% of VRTX's total ratings.

What is VRTX's price target?

Vertex Pharmaceuticals (VRTX) average price target is $521.64 with a range of $361 to $600, implying a 18.15% from its last price of $441.52. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Vertex Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for VRTX stock, the company can go up by 18.15% (from the last price of $441.52 to the average price target of $521.64), up by 35.89% based on the highest stock price target, and down by -18.24% based on the lowest stock price target.

Can Vertex Pharmaceuticals stock reach $700?

VRTX's average twelve months analyst stock price target of $521.64 does not support the claim that Vertex Pharmaceuticals can reach $700 in the near future.

What is Vertex Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $456 price target for Vertex Pharmaceuticals (VRTX) this month, up 3.28% from its last price of $441.52. Compared to the last 3 and 12 months, the average price target increased by 8.58% and increased by 12.46%, respectively.

What are Vertex Pharmaceuticals's analysts' financial forecasts?

Vertex Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $11.7B (high $12.33B, low $11.4B), average EBITDA is $5.27B (high $5.55B, low $5.14B), average net income is $4.79B (high $5.13B, low $4.55B), average SG&A $1.44B (high $1.51B, low $1.4B), and average EPS is $18.34 (high $19.66, low $17.42). VRTX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $12.76B (high $13.49B, low $12.4B), average EBITDA is $5.75B (high $6.08B, low $5.59B), average net income is $5.44B (high $5.84B, low $5.23B), average SG&A $1.57B (high $1.66B, low $1.52B), and average EPS is $20.83 (high $22.38, low $20.05).

Did the VRTX's actual financial results beat the analysts' financial forecasts?

Based on Vertex Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $8.93B, beating the average analysts forecast of $8.74B by 2.16%. Apple's EBITDA was $4.35B, beating the average prediction of $3.84B by 13.30%. The company's net income was $3.32B, missing the average estimation of $3.41B by -2.68%. Apple's SG&A was $944.7M, missing the average forecast of $1.02B by -7.76%. Lastly, the company's EPS was $12.97, missing the average prediction of $14.19 by -8.57%. In terms of the last quarterly report (Sep 2023), Vertex Pharmaceuticals's revenue was $2.48B, missing the average analysts' forecast of $2.5B by -0.72%. The company's EBITDA was $1.04B, missing the average prediction of $1.13B by -7.88%. Vertex Pharmaceuticals's net income was $1.04B, beating the average estimation of $1.03B by 0.84%. The company's SG&A was $263.8M, missing the average forecast of $307.28M by -14.15%. Lastly, the company's EPS was $4.01, beating the average prediction of $3.93 by 1.94%